Adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/HER2– breast cancer (LEADER)

Abstract Optimal timing and dosing of adjuvant cyclin-dependent kinase (CDK) 4/6 inhibitor in early breast cancer is controversial. This prospective phase II clinical trial investigated tolerability and safety of two ribociclib dosing schedules. Patients with stage I–III hormone receptor-positive (H...

Ful tanımlama

Kaydedildi:

Detaylı Bibliyografya
Asıl Yazarlar:	Laura M. Spring, Lauren Scarpetti, Arielle J. Medford, Andrzej Niemierko, Amy Comander, Therese Mulvey, Lowell Schnipper, Steven J. Isakoff, Beverly Moy, Seth A. Wander, Jennifer Shin, Zanta Ephrem, Anneke R. Laposta, Elyssa Denault, Elizabeth Abraham, Gayle Calistro, Ekaterina Kalashnikova, Angel Rodriguez, Minetta C. Liu, Alexey Aleshin, Jeffrey Peppercorn, Leif W. Ellisen, Aditya Bardia
Materyal Türü:	Artigo
Dil:	Inglês
Baskı/Yayın Bilgisi:	Nature Portfolio 2025-01-01
Seri Bilgileri:	npj Breast Cancer
Online Erişim:	https://doi.org/10.1038/s41523-024-00708-5
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!

Adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/HER2– breast cancer (LEADER)

Benzer Materyaller